Here’s what you need to know:
1. Kovanaze was approved by the FDA in June 2016.
2. Unlike standard dental anesthetic, which is administered through needle injection, Kovanaze is administered through a nasal spray.
3. Kovanaze is a topic, tooth nerve anesthetic containing tetracaineHCl (an ester local anesthetic) and oxymetazolineHCl (a vasoconstrictor).
4. The anesthetic is meant for restoratives procedures on Teeth 4 through 13 and A through J in adults and children who weigh more than 40 kilograms.
5. St. Renatus announced the launch of Kovanaze at the 2016 American Dental Association Meeting.
More articles on dental news:
Henry Schein to donate $50k to AAO’s Donated Orthodontic Services program: 3 notes
Patterson Dental enters distribution partnership with Heartland Dental: 3 notes
Community dental center for low-income seniors opens in San Diego: 5 notes
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place November 12–14 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
